Peptide T is a synthetic octapeptide (ASTTTNYT) derived from the V2 region of the HIV-1 gp120 envelope glycoprotein. Developed by Candace Pert and colleagues at the NIH, it was proposed to block HIV entry into CD4+ cells via receptor interaction.
Discovery and HIV Research
Candace Pert, known for her discovery of the opiate receptor, proposed that Peptide T could block HIV binding to its cellular entry receptor. The original hypothesis centered on CD4 and later CCR5 chemokine receptor interaction. Early in vitro studies showed some inhibitory effects on HIV binding, generating significant interest during the early AIDS research era.
Clinical Research in AIDS Dementia
Perhaps the most clinically relevant research involving Peptide T examined its potential effects on AIDS dementia complex (ADC), a neurological complication of HIV infection. A small double-blind trial suggested potential cognitive improvements in patients with ADC, though the study was limited in size and follow-up.
Neuroprotective Mechanisms
Beyond its antiviral applications, Peptide T has been studied for potential neuroprotective effects related to CCR5 chemokine receptor signaling. CCR5 is expressed on neurons and astrocytes, and chemokine signaling through this receptor plays roles in neuroinflammation relevant to multiple neurological conditions.
Current Status
Peptide T has not received regulatory approval for any indication. The emergence of highly effective antiretroviral therapy largely redirected HIV research priorities away from entry inhibitor peptides. Scientific interest now centers on its potential applications in neurological conditions involving CCR5 signaling.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.